title: Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
abstract: Obesity has a negative impact on health-related quality of life (HRQoL). The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m(-2) ] or overweight (BMI ≥ 27 kg m(-2) ) with comorbidity. Participants were advised on a 500 kcal d(-1) deficit diet and a 150-min week(-1) exercise programme and were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo. HRQoL was assessed using the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and Short-Form 36 (SF-36) v2 health questionnaires. Individuals on liraglutide 3.0 mg (n = 2046) had significantly greater improvements in IWQOL-Lite total score (10.6 ± 13.3) vs. placebo (n = 1020) (7.7 ± 12.8) and SF-36 physical (PCS) and mental (MCS) component summary scores (PCS, 3.6 ± 6.8; MCS, 0.2 ± 8.1) vs. placebo (PCS, 2.2 ± 7.7; MCS, -0.9 ± 9.1). The estimated treatment differences were IWQOL-Lite total score 3.1 (95% CI: 2.2; 4.0), P < 0.0001; SF-36 PCS 1.7 (95% CI: 1.2; 2.2), P < 0.0001 and MCS 0.9 (95% CI: 0.3; 1.5), P = 0.003. All subscales of the IWQOL-Lite and SF-36 were significantly improved with liraglutide 3.0 mg vs. placebo. More patients on liraglutide 3.0 mg experienced meaningful improvement on the IWQOL-Lite total (P < 0.0001) and the SF-36 PCS (P < 0.0001) scores.
authors.affiliation: Quality of Life Consulting, Durham, NC, USA.|Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.|Department of Health Studies, Sogn og Fjordane University College, Førde, Norway.|Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, Norway.
authors.forename: R L
authors.initials: RL
authors.lastname: Kolotkin
authors.affiliation: Nutrition and Metabolic Research Center, Scripps Clinic Department of Endocrine, La Jolla, CA, USA.
authors.forename: K
authors.initials: K
authors.lastname: Fujioka
authors.affiliation: Novo Nordisk A/S, Bagsvaerd, Denmark.
authors.forename: M L
authors.initials: ML
authors.lastname: Wolden
authors.affiliation: Novo Nordisk Inc., Plainsboro, NJ, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Brett
authors.affiliation: Optum Patient Insights, Lincoln, RI, USA.|National Research Centre for the Working Environment, Copenhagen, Denmark.|Department of Public Health, Section of Social Medicine, University of Copenhagen, Copenhagen, Denmark.
authors.forename: J B
authors.initials: JB
authors.lastname: Bjorner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D050177:Overweight / Q000188:drug therapy*; D011788:Quality of Life; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide
keywords: IWQOL-Lite; SF-36v2; liraglutide 3.0 mg; quality of life